Transient blocking of NK cell function with small molecule inhibitors for helper dependant adenoviral vector-mediated gene delivery

Manjunatha Ankathatti Munegowda and Jim Hu

Abstract

One major challenge in gene therapy is the host immune responses against viral vectors. Previous studies indicate the involvement of NK cells in stunted gene expression in viral vector mediated gene therapy. To understand the problem of the immune responses, we have developed an in-vitro co-culture system with human NK cell line, macrophages and airway epithelial cells. We showed that small molecule blockers, CAPE and ruxolitinib, for NF-κB and JAK-STAT pathways, respectively, significantly inhibited cytokine secretion by macrophages. When NK cells are co-cultured with helper-dependent adenoviral (HD-Ad) vector activated macrophages, IFN-γ cytokine expression by NK cells increased significantly, which was inhibited effectively by ruxolitinib and CAPE, and there was an additive effect when both inhibitors were used. We demonstrated that NK cells activated by cytokines produced by HD-Ad-activated macrophages kill HD-Ad vector transduced bronchial epithelial cells. This cell killing activity was significantly reduced by CAPE and ruxolitinib. Combination of these two inhibitors had an additive effect on inhibiting NK cell mediate killing of gene transduced cells. Transient inhibition of NK cell response at its peak may enhance sustained gene expression. Our data suggest that combination of CAPE and ruxolitinib may help in protecting gene transduced airway epithelial cells to prolong transgene expression.

Keywords: HD-Ad, NK cells, Macrophages, Janus kinase inhibitor, NF-κB inhibitor

Background

Our ability to detect genetic deletions and mutations that cause human diseases has immensely improved due to tremendous progress in human genetics [1, 2]. However, the current major hurdle to realize the full potential of therapeutic benefits from advancements in genetics is the slow progress in translating our knowledge into clinical therapeutic applications. Conceptually, correction of a genetic mutation/deletion that causes a disease should allow us to treat/cure the disease at its cause, not its symptoms, thereby, revolutionizing the human medicine. But, technically, it is difficult to deliver genetic materials, efficiently and safely despite the hype generated in early 1990s with only few success stories till now [3–5]. One of the major challenges faced in early gene therapy trials was the lack of novel delivery vectors with a high efficiency and easy production in high quality. There has been tremendous research in improving vectors to efficiently express genes in target cells [6, 7]. Our group has developed an efficient helper-dependent adenoviral (HD-Ad) vector to express the human cystic fibrosis transmembrane conductance regulator (CFTR) gene with epithelial cell specific K18 promoter for cystic fibrosis gene therapy [8].

Another major challenge has been the host immune responses that eliminate the cells transduced by gene therapy vectors [9, 10]. In airway gene delivery with adenoviral (Ad) vectors, apart from the physical barriers posed by mucus layer and tight junctions, both innate and adaptive immune responses were found to be a major problem that makes the transgene expression transient [10]. The innate immune response is caused by
the viral capsid proteins and the adaptive immune response is largely caused by the leaky expression of viral genes in addition to the capsid proteins. To reduce the adaptive immune response, a major improvement was made to Ad vectors by creating the HD-Ad vector in which all viral genes are deleted [11]. We and others have shown that HD-Ad vectors show long term transgene expression with reduced immune responses in mice [12, 13]. Because of the deletion of viral genes, this type of vector has very large gene carrying capacity (37 kb) and can be used to deliver large genes or multiple genes which cannot be handled by other commonly used vectors. We have further developed aerosolization protocol to achieve highly efficient gene delivery to rabbit lungs using HD-Ad vectors [14]. We have recently modified our protocol and achieved highly efficient vector delivery to pig lungs [8].

Since HD-Ad vectors contain the same capsid proteins as the conventional Ad vectors, they are expected to inflict innate immune responses. It is known that immune cells such as, macrophages [15, 16] and NK cells [17, 18] are involved in destroying gene therapy vectors or eliminating the transduced epithelial cells. Because robust levels of transgene expression can be maintained for a long time in rodents [6, 7], but was not achieved in large animal models, we need to understand how these innate immune cells affecting gene expression. Our studies with pig gene delivery show that IFN-γ is induced upon viral vector delivery [8]. Since NK cells are the major producers of IFN-γ in vivo [19], they are likely a barrier to sustained gene expression in pig airway. Thus, NK cell-mediated killing of gene transduced cells might be a major problem unnoticed in past clinical studies.

To understand the problem of immune responses we have developed an in-vitro co-culture system with human NK cell line, macrophages and airway epithelial cells. NK cell line, NK-92 is a human Natural Killer cell line derived from rapidly progressive non-Hodgkin’s lymphoma patient’s peripheral blood mononuclear cells [20]. THP-1 cells are monocyte cells line grown in suspension, they become attached once they are differentiated to mature macrophages in presence Phorbol 12-myristate 13-acetate (PMA) [21]. BEAS-2b, a cell line established from normal human bronchial epithelial cells. We used human cell lines in the study because of the lack of pig cell lines and reagents specific to pig cells. Eventually, HD-Ad gene therapy has to be tested in clinical trials; our results with human cell lines will be useful in designing human applications. To block NK cell, macrophage and epithelial cell interaction, and NK cell mediated killing of gene transduced cells, we targeted NF-kB and Janus kinase/signal transducers and activators of transcription (JAK-STAT) pathways. These pathways are critical for producing proinflammatory cytokines (such as, interferons, IL-6, IL-12, IL-15, IFN-γ) [22, 23]. We used small molecule blockers ruxolitinib and CAPE to block NF-kb and Jak-Stat pathways, respectively. Among the NF-kB inhibitors, CAPE [24] and Bay 11–7082 [25] are good candidates because of their potency. We used CAPE because Bay 11–7082 can only be dissolved in DMSO, because DMSO alone is shown to have influence on cell growth [26]. There are a quite number of inhibitors available for Jak-Stat pathways. We used Ruxolitinib which is a very potent inhibitor for Jak1 and Jak2 [27] and it is currently used in clinics for human therapy for myeloproliferative neoplasms [28–30]. In this paper, we demonstrated that these small molecule inhibitors can effectively block the activation of NK cells by HD-Ad vectors in our co-culture system.

**Results**

**Ruxolitinib and CAPE block activation of macrophages by HD-Ad vectors**

THP-1 cells were cultured in presence of Phorbol 12-myristate 13-acetate (PMA) for 48 h to differentiate them into macrophages. Differentiated THP-1 cells were harvested and cultured in presence of JAK inhibitor Ruxolitinib (1 μM) and NF-kB inhibitor CAPE (10 μM) for 24 h. Simultaneously, cohorts of these cells were also transduced with C4HSU HD-Ad vectors (5000 viral particles/cell). After 24 h of culturing them in presence of inhibitors, macrophages were harvested and total RNA was isolated and analyzed for expression of different cytokines by qRT-PCR analysis. Compared to untransduced macrophages, HD-Ad transduced cells showed significant increase in the expression of IL-15, IL-12α, TNF-α and IL-6 (p < 0.001) (Fig. 1). When macrophages were cultured in presence of ruxolitinib or CAPE, expression levels of IL-15, IL-12α, TNF-α and IL-6 decreased significantly compared to HD-Ad transduced cells without addition of inhibitors. When a combination of both ruxolitinib and CAPE were present, expression levels of IL-15 decreased to basal levels as seen in untransduced cells (Fig. 1). Particularly expression of human IL-6 decreased very significantly, indicating additive effect of ruxolitinib and CAPE. Untransduced cells in the presence of inhibitors did not show any effect on cytokine gene expression. There was no secretion of IFN-γ by macrophages or significant difference in secretion of IL-1β, IL-8 and IL-18 between vector-transduced and -untransduced macrophages (results not shown). Human bronchial epithelial cells showed an increase in IL-1β, IL-8 secretion (Additional file 1; Figure S1) when they were transduced with HD-Ad vectors.

**JAK and NF-kB inhibitors block HD-Ad-mediated activation of NK cells in co-culture with macrophages**

NK-92 cells were deprived from IL-2 for 48 h because NK –92 cells grown in presence of IL-2 are highly activated and are highly cytotoxic [31, 32]. It is well documented that IL-2 stimulation of NK cells induces
increased granzyme B expression [33, 34]. Secretion of cytotoxic granules is the dominant mode of cytotoxicity associated with NK cells. Granzyme B plays an important role in targeted killing of susceptible cells in both human and mouse [35–37]. IL-2 deprived NK-92 cells are co-cultured with activated macrophages (PMA activated THP-1 cells) in 1:1 ratio. They are co-cultured in presence and absence of Ruxolitinib and CAPE inhibitors. Simultaneously, a cohort of co-cultured cells were also transduced with C4HSU HD-Ad vectors (5000 viral particles/cell). After 24 h culturing, total RNA was isolated from the co-cultured cells and analyzed for expression of different cytokines by qRT-PCR analysis. Upon HD-Ad vector transduction, there was a very significant increase in expression of IL-15, IFN-γ, IL-12α, TNF-α and IL-6 (p < 0.001) (Fig. 2). IFN-γ is the cytokine secreted by NK cells alone in our co-culture system, there was no expression in macrophages (data not shown). When vector transduced NK-92 cells alone were cultured in presence and absence of inhibitors, there was no significant difference in any cytokine secretion (results are not shown). There was a significant decrease in INF-γ expression by NK cells cultured in presence of JAK2 and NF-κB inhibitors. There was an additive effect on INF-γ secretion in co-cultured cells when both the inhibitors were used (Fig. 2). Apart from IFN-γ, other cytokines like IL-15, IL-12α, TNF-α and IL-6 levels were also significantly decreased in ruxolitinib and CAPE inhibitor added cells compared to no-inhibitor. Similar to macrophage mono culture results there was very significant additive effect of inhibitors on human IL-6 expression in combination inhibitors (Fig. 2). Unlike human bronchial epithelial cells, NK-92 and THP-1 co-culture did not show any significant difference in IL-1β, IL-8 and IL-18 secretion upon HD-Ad transduction (Additional file 1: Figure S1).

**NK cell mediated killing of HD-Ad transduced epithelial cells can be blocked by Ruxolitinib and CAPE**

Mature macrophages from activated THP-1 cells are co-cultured over night with IL-2 deprived NK-92 cells in presence of the empty HD-Ad vector (C4HSU). Macrophage activated NK-92 cells were then transferred to overnight GFP-C4HSU vector (5000 viral particles/cell) transduced BEAS-2b cells for cytotoxicity assay. Co-cultures were done in presence and absence of ruxolitinib and CAPE.
alone, and also in presence of both the inhibitors. These co-cultures were incubated for five hours. After incubation for cytotoxicity, BEAS-2b cells were harvested and stained for early apoptosis marker allophycocyanin (APC)-conjugated Annexin V (Fig. 3) and dead (permeable) cell marker, 7-Aminoactinomycin D (7AAD), (Fig. 4). Stained cells were analysed on flow cytometer by gating on GFP positive BEAS-2b cells.

In BEAS-2b monoculture incubated with inhibitors in combination or alone did not show significant difference in apoptosis of HD-Adv transduced cells (Fig. 3Ba). There was a slight reduction of dead cells in combination inhibitor treated BEAS-2b cells (Fig. 4Ba). NK-92 cells activated by mature THP-1 cells showed significant increase in apoptosis of HD-Adv transduced BEAS-2b cells, 12.7 % in co-cultured NK-92 cells compared to 3.24 % in absence of NK-92 cells (Fig. 3). In parallel, 7AAD stained dead cells were also significantly more in NK-92 and activated THP-1 co-cultured BEAS-2b cells, 1.26 % in co-cultured NK-92 cells compared to 0.367 % in absence of NK-92 cells (Fig. 4). NK-92 mediated killing was effectively blocked by Ruxolitinib and CAPE, with combination of both the inhibitor there was additive effect in inhibiting cytotoxicity by NK-92 cells. When HD-Adv transduced BEAS-2b cells are co-cultured with THP-1 and NK-92 cells there was significant apoptosis in no inhibitor cohort of cells (12.7 %) and it significantly decreased with CAPE (7.41 %), Ruxolitinib (4.50 %) and there was additive impact with both the inhibitors (2.89 %) (Fig. 3Bb). In concurrence with apoptotic cell number, GFP positive dead cells were also significantly more in no inhibitor cohort of cells (1.26 %) and their numbers decrease significantly in CAPE (0.576 %), ruxolitinib (0.46 %) and with both inhibitors (0.381) showing additive effect of combination inhibitors (Fig. 4Bb).

When we used HD-Adv transduced NK-92 cells alone in cytotoxicity assay, they also showed increased cytotoxicity towards HD-Adv transduced BEAS-2b cells. Apoptosis induced by NK-92 cells on BEAS-2b cells was significantly high in no inhibitor cohort of cells (9.63 %), apoptotic cell number significantly decreased with CAPE (7.71 %), ruxolitinib (5.30 %) and it was 3.87 % with both the inhibitors (Fig. 3Bc). There was additive effect on 7AAD positive killed BEAS-2b cells when we used combination of both the inhibitors. Killed cells were significantly high in no inhibitor cohort of cells (0.879 %) compared to CAPE (0.619 %), ruxolitinib (0.495 %) and with both the inhibitors it was 0.204 % (Fig. 4Bc).
Discussions

Resident alveolar macrophages are abundant in lower respiratory tracts, acting as rapid first line of defense for invaders. Both macrophages and epithelial cells respond to viral infection by releasing soluble mediators, helping in the recruitment of innate and adaptive effector cells.
Fig. 4 NK cell mediated killing of HD-Ad gene transduced epithelial cells is blocked by Ruxolitinib and CAPE. NK-92 cells were deprived from IL-2 for 48 h and THP-1 cells were activated by 5 ng/ml PMA to prepare mature macrophages. Mature macrophages were harvested and co-cultured with NK-92 cells in presence of ruxolitinib or CAPE, and in presence and absence of both the inhibitors for 24 h. NK-92 cells alone were also cultured in presence of ruxolitinib or CAPE, and in presence and absence of both the inhibitors for 24 h. Both the cohorts of NK-92 and macrophages were transduced with C4HSU vector. Simultaneously, GFP-C4HSU transduced BEAS-2b cells were also cultured in presence of ruxolitinib or CAPE, and in presence and absence of both the inhibitors for 24 h. After culturing them for 24 h, NK-92 and macrophages were transferred to respective BEAS-2b cultures. After incubating those co-cultures for 5 h, BEAS-2b cells were harvested and stained for APC-Annexin V and 7AAD. Samples were run on flowcytometer and analysed by gating on GFP positive, gene transduced BEAS-2b cells. Percentages of 7AAD positive dead gene transduced BEAS-2b cells are depicted on upper right quadrant of panel (a). Percent dead cells from each row are depicted as separate bar diagram in panel (b) to better depict significant differences. Results from one experiment is depicted in the figure. The significance was calculated by one-way ANOVA with Tukey's multiple comparison. *p < 0.05, **p < 0.01, ***p < 0.001
In the process they recruit NK cells to the site of infection [38]. In an established mouse model of respiratory syncytial virus (RSV) disease, by depleting macrophages through clodronate liposome mediated depletion of macrophages. Macrophage depletion specifically affected NK cell recruitment, but not CD4 and CD8 T cells [38]. Up on viral infection macrophages have been shown to produce cytokines like IL-15, TNF-α and IL-12 [39–42]. Similarly, our HD-Ad vectors used for gene therapy did induce secretion of cytokines IL-15, IL-12, TNF-α and IL-6 when we transduced activated macrophages from THP-1 cells. Macrophages have also been shown to engulf viral vectors and destroy them through lysosomal degradation [43]; macrophage suppression may help in sustained gene expression in lung- gene therapy. In our study we have used small molecule blockers ruxolitinib and CAPE to block NF-κB and Jak-Stat pathways, respectively. Both ruxolitinib and CAPE have significant inhibition on cytokine secretion by macrophages. As both the inhibitors act on different pathways of activation, there was additive effect on inhibiting IL-6 and TNF-α secretion up on using combination of both the inhibitors. However, these findings are from an in vitro system, we need to further confirm them in suitable in vivo system. Recently, ruxolitinib is shown to inhibit dendritic cell mediate immune response through decreased IL-12 production [30]. NF-κB inhibitor CAPE was shown to have inhibitory effect on the production of pro-inflammatory cytokines from LPS-stimulated macrophages by inhibiting cytokine expression [44].

Macrophages and dendritic cells (DCs) are shown to regulate the NK cell activity through production of type I interferons, IL-12 and IL-15 [17, 45–49]. Current understanding of NK cell development involves the association of antigen presenting cells (APCs) for NK cell activation, because NK cells are not matured in bone marrow, they come out immature and get activated by APCs [50]. When NK cells are co-cultured with activated macrophages, in presence of our HD-Ad, IFN-γ cytokine expression by NK cells increased significantly. IFN-γ is only secreted by NK cells in our co-culture, it did not show any significant variation when NK cells alone were transduced, indicating the suppressive effect of inhibitors CAPE and ruxolitinib. IFN-γ expression decreased significantly up on incubating them with these inhibitors. There was additive inhibition on INF-γ secretion when both the inhibitors were used. In Rag2−/−γc−/− mice transplanted with human hematopoietic stem cells, membrane bound IL-15 is shown to effectively stimulate NK cells in to cytotoxic effector cells [51]. Although soluble cytokine has some response membrane bound IL-15 has significant influence on NK differentiation [51, 52]. To evaluate effect of contact dependant stimulation in our model, we did co-culture NK cells and macrophages in transwells with NK cells at the top and activated THP-1 cells at the bottom well. Twenty-four hrs after incubation both the cells were harvested separately and looked for expression levels of cytokines (results are not shown). There was no difference in expression levels of cytokines, indicating that membrane bound IL-15 alone may not have any significant influence in our gene delivery system.

We have demonstrated that NK cells activated by cytokines produced by HD-Ad vector activated macrophages kill HD-Ad vector transduced bronchial epithelial cells. The apoptotic cell number and number of vector-transduced epithelial cells killed are significantly reduced by NF-κB inhibitor CAPE and also by JAK inhibitor ruxolitinib. Combination of these two inhibitors has an additive effect on inhibiting NK cell mediate killing of gene transduced cells. In our previous study we have seen extensive increase in the IFN-γ at 5 to 7 days, which is secreted by NK cells, in our HD-Ad mediated gene therapy of pig lungs. Various viral infection models have also shown that NK cell response peaks at one week [53, 54]. Transient inhibition of this NK cell response at its peak will enhance sustained gene expression.

Conclusions

Based on our study with human cell lines, combination of CAPE and ruxolitinib will help in protecting gene transduced air way epithelial cells to prolong transgene expression by curtailing NK cell mediated deletion of gene transduced cells. NK cells are also shown to play an important role in priming and regulation of adaptive immune responses [55]. As depicted in Fig. 5 effective inhibition of NK cell response at its peak will also inhibit HD-Ad capsid mediated adaptive immune response. Cutting the arm leading to adaptive immune response will help in the redelivery of HD-Ad vectors for gene therapy as dampened antigen presentation happens with suppressed macrophage and NK cell response [56, 57].

Methods

Cell lines and reagents

NK-92 is a human Natural Killer cell line derived from rapidly progressive non-Hodgkin’s lymphoma patient’s peripheral blood mononuclear cells [20]. NK-92 cells were cultured in minimum essential medium (MEM) alpha without ribonucleosides and deoxyribonucleosides (Life-technologies, Burlington, ON, Canada), with 2 mM L-glutamine (Life-technologies, Burlington, ON, Canada), 1.5 g/L sodium bicarbonate (Sigma Aldrich, Missouri, USA), 0.2 mM inositol (Sigma Aldrich, Missouri, USA), 0.1 mM 2-mercaptoethanol (Sigma Aldrich, Missouri, USA), 0.02 mM folic acid(Sigma Aldrich, Missouri, USA), 100 U/ml recombinant IL-2 (Peprotech, NJ, USA), 12.5 % horse serum (Wisent Inc. Quebec, Canada) and 12.5 % fetal bovine serum (FBS) (Life-technologies, Burlington,
ON, Canada). THP-1, a monocyte cell line [58] was main-
tained in RPMI-1640 (Lifetechnologies, Burlington, ON,
Canada) with 10 % FBS and 0.05 mM 2-mercaptoethanol.
THP-1 cells were differentiated to mature macrophages in
presence of 5 ng/ml Phorbol 12-myristate 13-acetate
(PMA) for 48 h. PMA was obtained from Sigma Aldrich,
Missouri, USA. BEAS-2b, a cell line established from nor-
mal human bronchial epithelial cells, was obtained from
the American Type Culture Collection (ATCC). These cells
were maintained in Dulbecco's Modified Eagle's Medium
(DMEM) (Lifetechnologies, Burlington, ON, Canada) with
10 % FBS. Ruxolitinib, a Janus kinase inhibitor was ob-
tained from LC laboratories Woburn, MA, USA. Caffeic
acid phenethyl ester (CAPE) was obtained from Tocris bio-
science, Bristol, United Kingdom.

**Helper dependant Adenoviral vector production**

Design and production of the HD-Ad vectors expressing
GFP and empty/pC4HSU vectors used in this study were
described previously [12, 59]. Briefly a GFP gene expres-
sion cassette was cloned into the pC4HSU vector which
was linearized with a restriction enzyme, Pme I, for viral
production. HD-Ad vectors were produced and purified
by CsCl gradient centrifugation.

**Quantitative Real time PCR**

For mRNA expression analysis, total RNA was isolated
form cells by using the Qiagen RNeasy kit (Qiagen,
Mississauga, Ontario, Canada) according to the manu-
facturer’s instructions, followed by DNase digestion. One
μg of total RNA obtained was reverse transcribed using
random hexamers and SuperScript II reverse transcriptase
(Invitrogen, Carlsbad, CA, USA) following the manu-
ufacturer’s protocol. Ten ng of cDNA were then used as
template for real-time PCR using SYBR Green in ABI
prism 7000 (Life Technologies Inc., Burlington, ON,
Canada). The primers used for detecting different cytokine
levels are as follows: hIL-15 Forward-CAGAAGCCAAC
TTGGGTGAATG and Reverse- GGGTGAACATCACTTT
CCGTATA, hIL-12α Forward-GGCGAAAATTCATTG
GATGTTA ATT, hIFN-γ Forward- GGCCTCTCTGCTTG
TTAC TG and Reverse- CTGTCACTCTTCCTTCAATTC,
hTNF-α Forward- GGTGCTGTTCTCTGCTCAGCT
and Reverse- GGTGAGAGATGATCAGTGCT TG, hIL6
Forward- GGTGCTGTTCTTCAATTC, and Reverse-
CTGTCACAGCTCTGGCTTG.

**Flowcytometric apoptosis and cytotoxicity assay**

NK-92 cells were cultured in complete NK-92 growth
medium without IL-2 supplement for 48 h, to deprive
them from IL-2. Simultaneously, THP-1 cells were dif-
erentiated into mature macrophages in presence of
5 ng/ml PMA for 48 h. After 48 h mature macrophages
attached to culture plates were harvested by using Accutase
(Sigma-Aldrich Canada Co. Oakville, Ontario Canada) and
cultured with IL-2 deprived NK-92 cells in 1:1 concen-
tration, in presence and absence of different inhibitors and
C4HSU vector (5000 viral particles/cell) as depicted in fig-
ures, for one day. Mono cultures of IL-2 deprived NK-92
cells were also incubated with and without inhibitors, and
C4HSU vector (5000 viral particles/cell) as depicted in fig-
ures, for one day. Simultaneously, one day after starting the
IL-2 deprival for NK-92 and THP-1 differentiation to
macrophages, BEAS-2b cells were plated on to 60 mm tissue culture dishes at 2X10^5 cells per plate. Next day, media in those plates were replaced with or without GFP expressing vector (5000 viral particles/cell) as depicted in figure, in serum free RPMI-1640 for vector transduction. After two hours the media in all BEAS-2b plates were replaced with RPMI-1640 with 10% FCS and cultured for one day. Later, co-cultured NK-92 and macrophages, and also mono cultured NK-92 were added to respective BEAS-2b plates as depicted in figures, in 5:1 (BEAS-2b: NK-92: THP-1) ratio. (Note: when we transfer co-cultured NK-92 and macrophages, though we mix and transfer those cells to BEAS-2b plates we are not transferring attached macrophages). Five hours after co-culturing these cells together, BEAS-2b cells were harvested using Trypsin EDTA (Lifetechnologies, Burlington, ON, Canada). Harvested cells were washed with PBS, and stained with Annexin V-APC (eBioscience Inc., San Diego, CA, USA) and 7AAD (eBioscience Inc., San Diego, CA, USA) for 30 min, in Annexin staining buffer (eBioscience Inc.) as per manufacturers protocol. After 30 min 300 μl of Annexin binding buffer was added and samples were analysed on BD LSR-II flowcytometer (BD Biosciences, Mississauga, ON, Canada). GFP positive vector transduced BEAS-2b cells were gated and further analysed for apoptotic Annexin V and killed 7AAD positive population of GFP transduced BEAS-2b cells.

Statistical analysis
All experiments were performed at least for 3 times, with representative experiments shown in figures. To test for statistical significance one-way ANOVA was done with Tukey’s post hoc test, and Mann–Whitney test, using Prism 5 software.

Supplementary information is available at Cell and Biosciences website.

Additional file

Additional file 1: Figure S1. HD-Adv transduced bronchial epithelial cells produce pro-inflammatory cytokines. One cohort of BEAS-2b cells were transduced with HD-Adv and other cohort was not transduced and cultured for 24 h. After culturing them for 24 h total RNA was isolated and analysed by qPCR to look for relative expression of different cytokines. Relative expression of cytokines from one experiment is depicted in the figure. The significance was calculated by Mann–Whitney U test.

Competing interests
The authors declare that they have no competing interests

Authors’ contributions
MAM contributed towards experiments performed in the study and drafted the manuscript. Both MAM and JH were involved in conception and design, and revised and approved the manuscript.

Acknowledgements
We thank Dr. Armand Keating for providing NK-92 and THP-1 cells, and Rongqi Duan for HD-Ad vector production. This study was supported by CIHR grant MOP 125882 to JH. Manjunatha Ankathatti Munegowda was supported by Restrecom award from RTC and Garron Family Cancer Centre funding from The Hospital for Sick Children, Toronto, ON, Canada.

Received: 26 March 2015 Accepted: 5 June 2015
Published online: 11 June 2015

References
1. Offit K. Personalized medicine: new genomics, old lessons. Hum Genet. 2011;130(1–3):14.
2. Mestan KK, Ikhanoff L, Mouli S, Lin S. Genomic sequencing in clinical trials. J Transl Med. 2011;9:222.
3. Maguire AM, Simonelli F, Pierce EA, Pugh JR E, Mingozi F, Bennicelli J, et al. Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med. 2008;358(21):2240–8. doi:10.1056/NEJMoa0802315.
4. Bennett J, Afsari M, Wellman J, Marshall RA, Cykowitski LL, Chung DC, et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med. 2012;4(120):120ra15. doi:10.1126/scitranslmed.3002865.
5. MacLaren RE, Groppe M, Barnard AR, Cottrill CL, Talmochova T, Seymour L, et al. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet. 2014;383(9923):1129–37. doi:10.1016/ S0140-6736(13)62117-0.
6. Koehler DR, Fridova H, Leung K, Louca D, Ng P, et al. Aerosol delivery of an enhanced helper-dependent adenovirus formulation to rabbit lung using an intratracheal catheter. J Gene Med. 2005;7(11):1409–20. doi:10.1002/jgm.797.
7. Koehler DR, Sajjan U, Chow YH, Martin B, Kent G, Tanswell AK, et al. Protection of Cfr knockout mice from acute lung infection by a helper-dependent adenovector expressing Cfr in airway epithel. Proc Natl Acad Sci U S A. 2003;100(26):15364–9. doi:10.1073/pnas.1536478100.
8. Cao H, Machuca TN, Yeung JC, Wu J, Duan C, et al. Efficient gene delivery to pig airway epithelia and submucosal glands using helper-dependent adenovector vectors. Mol Ther Nucleic Acids. 2013;2:e127. doi:10.1038/ mtDNA.2013.55.
9. Dai Y, Schwarz EM, Gu D, Zhang WW, Sarvetnick N, Verma IM. Cellular and humoral immune responses to adenovector containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci U S A. 1995;92(5):1401–5.
10. Yang Y, Li Q, Ertl HC, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol. 1999;73(4):1649–58.
11. Parks RI. Improvements in adenoviral vector technology: overcoming barriers for gene therapy. Clin Genet. 2000;58(1):1–11.
12. Toietta G, Koehler DR, Finegold MJ, Lee B, Hu J, Beaudet AL. Reduced inflammation and improved airway expression using helper-dependent adenoviral vectors with a K18 promoter. Mol Ther. 2003;5(7 Pt 1):649–58.
13. Cao H, Koehler DR, Hu J. Adenoviral vectors for gene replacement therapy. Viral Immunol. 2004;17(3):27–33.
14. Koehler DR, Fridova H, Leung K, Louca E, Palmer D, Ng P, et al. Aerosol delivery of an enhanced helper-dependent adenovirus formulation to rabbit lung using an intratracheal catheter. J Gene Med. 2005;7(11):1409–20.
15. Ziegellner Z, Otake K, Hossain SA, Berdlov P, Trapnell BC. Internalization of adenovirus by alveolar macrophages initiates early proinflammatory signaling during acute respiratory tract infection. J Virol. 2000;74(9):6655–67.
16. Worqall S, Leopold PL, Wolff G, Ferri B, Van Roijen N, Cristal RG. Role of alveolar macrophages in rapid elimination of adenovirus vectors administered to the epithelial surface of the respiratory tract. Hum Gene Ther. 1997;8(14):1675–84.
17. Zhu J, Huang X, Yang Y. A critical role for type I IFN-dependent NK cell activation in innate immune elimination of adenovirus vectors in vivo. Mol Ther. 2008;16(7):1300–7.
18. Zhu J, Huang X, Yang Y. NKGD2 is required for NK cell activation and function in response to E1-deleted adenovirus. J Immunol. 2010;185(12):7480–6.
19. Uemura A, Takehara T, Miyagi T, Suzuki T, Tatsumi T, Ohkawa K, et al. Natural killer cell is a major producer of interferon gamma that is critical for the IL-12-induced anti-tumor effect in mice. Cancer Immunol Immunother. 2010;59(3):453–63. doi:10.1007/s00262-009-0764-x.
20. Tam YK, Maki G, Miyagawa B, Hennemann B, Tonn T, Klingemann HG. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum Gene Ther. 1999;10(8):1359–73. doi:10.1089/10430399950018030.
